Stockscreener 앱 받기
16.24
0.18%
-0.04
전일 마감가:
$16.28
열려 있는:
$16.16
하루 거래량:
1.72M
Relative Volume:
0.17
시가총액:
$18.67B
수익:
$14.57B
순이익/손실:
$-296.50M
주가수익비율:
-62.70
EPS:
-0.259
순현금흐름:
$1.64B
1주 성능:
-7.93%
1개월 성능:
-0.12%
6개월 성능:
+2.91%
1년 성능:
+60.57%
1일 변동 폭
$15.98
$16.32
1주일 범위
$15.98
$18.39
52주 변동 폭
$9.425
$18.39
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.25 | 18.70B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.45 | 55.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 43.73B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.61 | 42.51B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
72.60 | 31.14B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
520.03 | 22.11B | 3.17B | 1.29B | 1.01B | 27.09 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run - Sahm
Why Viatris (VTRS) Is Down 6.4% After Boosting Guidance And Completing A $1.15 Billion Buyback - simplywall.st
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program - finance.yahoo.com
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval - finance.yahoo.com
Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress - finance.yahoo.com
Viatris Inc. (VTRS) Stock Forecasts - Yahoo! Finance Canada
Viatris (VTRS) Stock Looks Stuck Between Higher Guidance And Wider Losses - Sahm
Viatris Inc. (US92556V1061.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris Earnings: Good Performance in Key Regions and Outlook Increase Make for a Solid Quarter - Morningstar
Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc. - VisionMonday.com
Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside - TradingView
Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ... - finance.yahoo.com
Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overv - GuruFocus
Viatris Inc. stock falls Thursday, underperforms market - marketwatch.com
Viatris Inc Q2 2026: Revenue $3.76B, EPS $(0.10) — 10-Q Summary - TradingView
Viatris (NASDAQ: VTRS) swings to H1 2026 profit as revenue tops $7.27B - Stock Titan
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Viatris Q2 2026 slides: strong beat, raised outlook, H2 headwinds - Investing.com
Viatris Q2 2026 slides: strong results lift guidance amid H2 headwinds - Investing.com
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook - TradingView
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth - Morningstar
Viatris Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:VTRS) 2026-08-06 - Seeking Alpha
Viatris stock hits 52-week high at 18.27 USD - Investing.com
Viatris Q2 2026 slides: strong beat drives guidance raise - Investing.com
FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares - Stock Titan
Earnings call transcript: Viatris tops Q2 2026 estimates, lifts outlook - Investing.com
Viatris Announces Quarterly Dividend - marketscreener.com
Viatris Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics - finance.yahoo.com
Viatris Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Viatris Inc. R (VIA.DE) Q2 FY2026 earnings call transcript - finance.yahoo.com
Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates - finance.yahoo.com
Viatris' Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance - marketscreener.com
(VTRS) Viatris Expects 2026 Revenue Range $14.55B$14.95B, vs. FactSet Est of $14.79B - marketscreener.com
(VTRS) Viatris Expects 2026 Adjusted EPS Range $2.45$2.59, vs. FactSet Est of $2.45 - marketscreener.com
Viatris raises annual profit forecast on branded drug strength - marketscreener.com
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 - finance.yahoo.com
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M - Seeking Alpha
Earnings Flash (VTRS) Viatris Inc. Reports Q2 Revenue $3.76B, vs. FactSet Est of $3.68B - marketscreener.com
Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60 - marketscreener.com
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris Reports Second-Quarter 2026 Financial Results - TradingView
Viatris Q2 preview: Analysts see profits softening amid pressure on generics business (VTRS:NASDAQ) - Seeking Alpha
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - finance.yahoo.com
Is Wall Street Bullish or Bearish on Viatris Stock? - webull.com
Viatris Inc. declares Quarterly Dividend, Payable on September 16, 2026 - marketscreener.com
Viatris Gears Up to Report Q2 Earnings: What's in the Cards? - finance.yahoo.com
Viatris Inc expected to post earnings of 60 cents a shareEarnings Preview - TradingView
Viatris: A Reasonable Valuation (NASDAQ:VTRS) - Seeking Alpha
Viatris (VTRS) Wins FDA Approval For Gwyn Lo Contraceptive Patch - finance.yahoo.com
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.74%
자본화:
|
볼륨(24시간):